Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: Data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (

Marco Floridia, R. Bucciardini, V. Fragola, C. M. Galluzzo, G. Giannini, M. F. Pirillo, R. Amici, M. Andreotti, D. Ricciardulli, C. Tomino, S. Vella, N. Abrescia, L. Boccia, E. Butrico, A. Vegezio, A. Busto, A. Aceti, M. S. Mura, G. N. Calia, C. LoviguS. Babudieri, S. Oggiano, R. Masia, F. Aiuti, I. Mezzaroma, G. D'Offizi, M. Carlesimo, A. Giovannetti, E. Pinter, F. Alberici, M. Sisti, D. Sacchini, A. Faggi, F. Paolillo, G. Angioni, G. Meloni, S. Angioni, G. Albeltino, F. Porcu, D. Bassetti, G. Gatti, A. Di Biagio, G. Mazzarello, L. Bonazzi, E. Barchi, L. Testa, M. A. Ursitti, G. Zoboli, G. P. Cadeo, C. Barni, D. Bertelli, P. Cadrobbi, A. Cattelan, F. Meneghetti, A. Sattin, R. Scaggiante, D. Giacomazzi, L. Caggese, M. C. Moioli, A. Volonterio, I. Schlacht, I. Errante, L. Irato, R. Caputo, M. Cusini, A. Cagnel, L. Valsecchi, R. Beretta, G. Carosi, A. Chiodera, F. Castelli, L. Tomasoni, A. A. Cattane, P. Nasta, F. Chiodo, V. Colangeli, R. Manfredi, M. Borderi, C. Donzelli, E. Guerra, A. Chirianni, M. Gargiulo, V. Montesarchio, R. Punzi, V. Sangiovanni, R. Gnarini, R. Ciammarughi, M. Arlotti, M. L. Martelli, G. Romagnoli, A. Boschi, A. Colomba, T. Prestileo, S. Fundaró, F. Di Lorenzo, M. Mineo, E. R. Dalle Nogare, E. Concia, G. Di Perri

Research output: Contribution to journalArticlepeer-review

Abstract

Background. Most of the studies evaluating rash in HIV-positive patients have focused on nonnucleoside reverse transcriptase inhibitors (NNRTI), particularly nevirapine, and little is known about the occurrence of rash and the risk factors for its development in patients receiving regimens not based on NNRTI. Methods. We evaluated all cases of rash observed during a 48-week randomized multicentre trial in 1251 nucleoside-experienced patients who started treatment with protease inhibitors (ritonavir or indinavir) at CD4 counts below 50 cells/μL. Incidence rates for rash were calculated according to gender, clinical status, age, use of highly active antiretroviral therapy (HAART), Pneumocystis carinii pneumonia (PCP) prophylaxis and use of individual antiretroviral drugs at enrolment. Differences between groups defined according to the above characteristics were tested for statistical significance using the log-rank test in a Kaplan-Meier survival analysis. All factors that gave results in the univariate analyses below the significance level of 0.05 were included in a multivariate analysis using a Cox regression model. Results. During a follow-up period of 9690 person-months, 66 patients (5.3%) developed rash (0.68 events/100 person-months). In the univariate analyses, risk of rash did not differ with trial treatment (indinavir or ritonavir), clinical status, PCP prophylaxis, or age. During follow-up, rash was observed in 7.5% of enrolled women and in 4.5% of enrolled men (P= 0.03). Serious rash occurred in 4.5% of enrolled women and in 1.6% of enrolled men (P= 0.003). Use of HAART (P

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalHIV Medicine
Volume5
Issue number1
DOIs
Publication statusPublished - Jan 2004

Keywords

  • HIV
  • Protease inhibitors
  • Rash

ASJC Scopus subject areas

  • Virology
  • Medicine(all)
  • Immunology

Fingerprint Dive into the research topics of 'Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: Data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels ('. Together they form a unique fingerprint.

Cite this